Mammary Cell News Volume 7.08 | Mar 5 2015

Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression
Because gene profiling studies have revealed that methionine depletion increases TNF-related apoptosis-inducing ligand receptor-2 (TRAIL-R2) mRNA, scientists postulated that methionine stress sensitizes breast cancer cells to proapoptotic TRAIL-R2 agonists. The effects of methionine depletion on TRAIL receptor expression and sensitivity to chemotherapy or a humanized agonistic TRAIL-R2 monoclonal antibody were determined. [Clin Cancer Res] Abstract

WNT-1 Inducible Signaling Pathway Protein-1 Enhances Growth and Tumorigenesis in Human Breast Cancer
Researchers demonstrated that human breast cancer tissues had higher WNT1 inducible signaling pathway protein 1 (WISP1) mRNA expression than normal breast tissues and that treatment of recombinant WISP1 enhanced breast cancer cell proliferation. [Sci Rep] Full Article

Lipid Nanocarriers of a Lipid-Conjugated Estrogenic Derivative Inhibit Tumor Growth and Enhance Cisplatin Activity against Triple-Negative Breast Cancer: Pharmacokinetic and Efficacy Evaluation
Investigators formulated a nontoxic, cationic, lipid-conjugated estrogenic derivative, with demonstrated anticancer activity, for oral delivery in mice bearing triple negative breast cancer as xenograft tumors. [Mol Pharm] Abstract

COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation
The functional roles of microRNA-526b (miR-526b) in breast cancer and the mechanistic role of EP4 signaling in miR-526b up-regulation were examined. [Mol Cancer Res] Abstract

Gene Signatures of 1,25-Dihydroxyvitamin D₃ Exposure in Normal and Transformed Mammary Cells
To elucidate potential mediators of vitamin D receptor action in breast cancer, investigators profiled the genomic effects of its ligand 1,25-dihydroxyvitamin D₃ in cells derived from normal mammary tissue and breast cancer. [J Cell Biochem] Abstract

Knockdown of UbcH10 Enhances the Chemosensitivity of Dual Drug Resistant Breast Cancer Cells to Epirubicin and Docetaxel
The authors found that the expression of ubiquitin-conjugating enzyme H10 (UbcH10) was up-regulated in some breast cancer tissues and five cell lines. They established a dual drug resistant cell line MCF-7/EPB (epirubicin)/TXT (docetaxel) and a lentiviral system expressing UbcH10 shRNA to investigate the effects of UbcH10 knockdown on the chemosensitivity of MCF-7/EPB/TXT cells to epirubicin and docetaxel. [Int J Mol Sci] Abstract | Download Full Article

Effects of the Knockdown of Death-Associated Protein 3 Expression on Cell Adhesion, Growth and Migration in Breast Cancer Cells
The authors intended to determine the role of death-associated protein 3 (DAP3) in cancer cell behaviour in the context of human breast cancer. They developed knockdown sub-lines of MCF7 and MDA-MB231, and performed growth, adhesion, invasion assays and electric cell-substrate impedance sensing studies of post-wound migration of the cells. [Oncol Rep] Abstract

CLINICAL RESEARCH

Safety and Activity of Alisertib, an Investigational Aurora Kinase A Inhibitor, in Patients with Breast Cancer, Small-Cell Lung Cancer, Non-Small-Cell Lung Cancer, Head and Neck Squamous-Cell Carcinoma, and Gastro-Oesophageal Adenocarcinoma: A Five-Arm Phase II Study
Alisertib is an investigational, oral, selective inhibitor of aurora kinase A. Researchers aimed to investigate the safety and activity of single-agent alisertib in patients with predefined types of advanced solid tumors. [Lancet Oncol] Abstract

Neoadjuvant Dual HER2-Targeted Therapy with Lapatinib and Trastuzumab Improves Pathologic Complete Response in Patients with Early Stage HER2-Positive Breast Cancer: A Meta-Analysis of Randomized Prospective Clinical Trials
Investigators performed a meta-analysis of prospective randomized clinical trials that examined the effect of adding lapatinib to trastuzumab and neoadjuvant chemotherapy on pathologic complete response rate. [Oncologist] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Spectrum Pharmaceuticals In-Licenses Poziotinib, a Novel Pan-HER Inhibitor with Clinical Activity in Several Solid Tumors, from Hanmi Pharmaceuticals
Spectrum Pharmaceuticals announced it has entered into a licensing agreement with Hanmi Pharmaceuticals for poziotinib, a drug being investigated for the treatment of cancer. [Spectrum Pharmaceuticals, Inc.]
Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the mammary cell community.

NEW Bioinformatics Officer – Cancer Drug Discovery and Development (Institute of Cancer Research)

Scientist – Mammary Cell Research (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Scientist – Cell Culture Support Products (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Postdoctoral Position – Breast Cancer Signaling (Weizmann Institute of Science)

Clinician Scientist (National University of Singapore)

Postdoctoral Associate – LincRNAs in Tumorigenesis (Fox Chase Cancer Center)

Postdoctoral Fellow – Stem Cells and Breast Cancer (Albert Einstein College of Medicine)

Director – Vector Production (Sangamo BioSciences, Inc.)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.